Loading...
•
Mar 31, 2022
Day One Q1 2022 Earnings Report
Announced first quarter 2022 financial results and provided a business update.
Key Takeaways
Day One Biopharmaceuticals reported first quarter 2022 financial results. The company's cash and cash equivalents totaled $262.7 million. Net loss totaled $27.7 million for the quarter.
Initial data from pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG) expected in June 2022
Company plans to initiate pivotal Phase 3 FIREFLY-2 clinical trial evaluating tovorafenib as a first-line therapy in pLGG in the second quarter of 2022
Initiated Phase 1b/2 combination study with tovorafenib and pimasertib in RAF-altered solid tumors
Day One anticipates releasing topline results from the fully-enrolled pivotal study in the first quarter of 2023.
Forward Guidance
Management believes it has sufficient capital resources to fund anticipated operations into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...